{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:50:05Z","timestamp":1790949005452,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hyperphosphatemia, reduced active vitamin D (1,25-OH2 vitamin D), and hypercalciuria. Due to its rarity, non-specialized physicians often lack experience managing HypoPT. To address this, expert consensus statements were developed for the DACH region (Germany, Austria, Switzerland), considering regional differences and high HypoPT incidence. These statements aim to enhance adherence to guideline recommendations and improve non-specialist knowledge. From December 2023 to April 2024, three rounds of a Delphi consensus survey were conducted with seven DACH-region clinical experts. Consensus was defined as agreement among at least 6 of 7 participants (85%). Experts agreed surgery accounts for 90% of chronic HypoPT cases. Common symptoms include paresthesia, muscle cramps, and fatigue. Albumin-adjusted serum calcium should be measured 12\u201324\u00a0h post-surgically, within 2\u00a0weeks, and every 3\u20136\u00a0months thereafter. Key treatment goals are maintaining albumin-adjusted serum calcium in the lower normal range, symptom control, and quality of life. Long-term objectives include avoiding hypo- and hypercalcemia phases and disease-related complications. Failure of calcium and active vitamin D therapy is defined by persistent symptoms, hospitalization, laboratory values outside of the normal range, or medication intolerance. Experts emphasized using HypoPT-specific, validated quality-of-life questionnaires. This consensus provides practical guidance for non-specialists in diagnosing, treating, and monitoring HypoPT, improving care in German-speaking regions.<\/jats:p>","DOI":"10.1007\/s00223-025-01414-5","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T07:44:04Z","timestamp":1754984644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Consensus-Based Recommendations for the Diagnosis, Treatment, and Monitoring of Hypoparathyroidism: Insights from the DACH Region"],"prefix":"10.1007","volume":"116","author":[{"given":"Elena","family":"Tsourdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kreissl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1767-5699","authenticated-orcid":false,"given":"Tobias","family":"Vogelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s15006-019-1174-4","volume":"161","author":"S Petersenn","year":"2019","unstructured":"Petersenn S, Bojunga J, Brabant G et al (2019) Hypoparathyroidism\u2014un underestimated problem? MMW Fortschr Med 161:12\u201320. https:\/\/doi.org\/10.1007\/s15006-019-1174-4","journal-title":"MMW Fortschr Med"},{"key":"1414_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D et al (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101:2273\u20132283. https:\/\/doi.org\/10.1210\/jc.2015-3907","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Brandi ML, Cusano NE et al (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313\u20132324. https:\/\/doi.org\/10.1210\/jc.2015-3910","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, L\u00f8v\u00e5s K, Debowska A et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045\u20133053. https:\/\/doi.org\/10.1210\/jc.2016-1477","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00223-018-0405-5","volume":"103","author":"L Cianferotti","year":"2018","unstructured":"Cianferotti L, Parri S, Gronchi G et al (2018) Prevalence of chronic hypoparathyroidism in a Mediterranean region as estimated by the analysis of anonymous healthcare database. Calcif Tissue Int 103:144\u2013150. https:\/\/doi.org\/10.1007\/s00223-018-0405-5","journal-title":"Calcif Tissue Int"},{"key":"1414_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jbmr.3329","volume":"33","author":"T Vadiveloo","year":"2018","unstructured":"Vadiveloo T, Donnan PT, Leese GP (2018) A Population-Based Study of the Epidemiology of Chronic Hypoparathyroidism. J Bone Miner Res 33:478\u2013485. https:\/\/doi.org\/10.1002\/jbmr.3329","journal-title":"J Bone Miner Res"},{"key":"1414_CR7","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke BL, Brown EM, Collins MT et al (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284\u20132299. https:\/\/doi.org\/10.1210\/jc.2015-3908","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-0037-1616609","volume":"54","author":"FA Verburg","year":"2015","unstructured":"Verburg FA (2015) Is thyroid surgery performed too often in Germany? Nuklearmedizin 54:101\u2013105","journal-title":"Nuklearmedizin"},{"key":"1414_CR9","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277\u20132285. https:\/\/doi.org\/10.1002\/jbmr.1979","journal-title":"J Bone Miner Res"},{"key":"1414_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/cen.13395","volume":"87","author":"KVS Hari Kumar","year":"2017","unstructured":"Hari Kumar KVS, Patnaik SK (2017) Incidence of parathyroid disorders in Indian adult male population: a 25-year follow-up study. Clin Endocrinol (Oxf) 87:605\u2013608. https:\/\/doi.org\/10.1111\/cen.13395","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1414_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-024-07352-6","volume":"36","author":"Y-Y Yang","year":"2025","unstructured":"Yang Y-Y, Deng Y-H, Sun L-H et al (2025) Hypoparathyroidism: similarities and differences between Western and Eastern countries. Osteoporos Int 36:391\u2013402. https:\/\/doi.org\/10.1007\/s00198-024-07352-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"1414_CR12","first-page":"11","volume":"2","author":"H Siggelkow","year":"2017","unstructured":"Siggelkow H (2017) Standardtherapie und Ausblick bei der Behandlung des Hypoparathyreoidismus. Endokrinologie Informationen 2(1):11\u201314","journal-title":"Endokrinologie Informationen"},{"key":"1414_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3803\/EnM.2015.30.4.436","volume":"30","author":"L Rejnmark","year":"2015","unstructured":"Rejnmark L, Underbjerg L, Sikjaer T (2015) Hypoparathyroidism: replacement therapy with parathyroid hormone. Endocrinol Metab 30:436. https:\/\/doi.org\/10.3803\/EnM.2015.30.4.436","journal-title":"Endocrinol Metab"},{"key":"1414_CR14","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/jbmr.4673","volume":"37","author":"L Yao","year":"2022","unstructured":"Yao L, Hui X, Li M et al (2022) Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review. J Bone Miner Res 37:2642\u20132653. https:\/\/doi.org\/10.1002\/jbmr.4673","journal-title":"J Bone Miner Res"},{"key":"1414_CR15","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT et al (2011) Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317\u20132337. https:\/\/doi.org\/10.1002\/jbmr.483","journal-title":"J Bone Miner Res"},{"key":"1414_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D (2008) Hypoparathyroidism. N Engl J Med 359:391\u2013403. https:\/\/doi.org\/10.1056\/NEJMcp0803050","journal-title":"N Engl J Med"},{"key":"1414_CR17","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/jbmr.4714","volume":"37","author":"JL Pasieka","year":"2022","unstructured":"Pasieka JL, Wentworth K, Yeo CT et al (2022) Etiology and pathophysiology of hypoparathyroidism: a narrative review. J Bone Miner Res 37:2586\u20132601. https:\/\/doi.org\/10.1002\/jbmr.4714","journal-title":"J Bone Miner Res"},{"key":"1414_CR18","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan AA, Koch CA, Van Uum S et al (2019) Standards of care for hypoparathyroidism in adults: a Canadian and international consensus. Eur J Endocrinol 180:P1\u2013P22. https:\/\/doi.org\/10.1530\/EJE-18-0609","journal-title":"Eur J Endocrinol"},{"key":"1414_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.800119","author":"EV Kovaleva","year":"2022","unstructured":"Kovaleva EV, Eremkina AK, Elfimova AR et al (2022) The Russian registry of chronic hypoparathyroidism. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2022.800119","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1414_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bjoms.2023.10.001","volume":"61","author":"SL Roberts","year":"2023","unstructured":"Roberts SL, El-Shikh M, Alam P, Borumandi F (2023) Incidence of post-surgical hypoparathyroidism (POSH) after total thyroidectomy. Br J Oral Maxillofac Surg 61:679\u2013685. https:\/\/doi.org\/10.1016\/j.bjoms.2023.10.001","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1414_CR21","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1530\/EJE-21-1044","volume":"186","author":"J Bollerslev","year":"2022","unstructured":"Bollerslev J, Rejnmark L, Zahn A et al (2022) European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur J Endocrinol 186:R33\u2013R63. https:\/\/doi.org\/10.1530\/EJE-21-1044","journal-title":"Eur J Endocrinol"},{"key":"1414_CR22","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1002\/jbmr.4691","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan AA, Bilezikian JP, Brandi ML et al (2022) Evaluation and management of hypoparathyroidism summary statement and guidelines from the Second International Workshop. J Bone Miner Res 37:2568\u20132585. https:\/\/doi.org\/10.1002\/jbmr.4691","journal-title":"J Bone Miner Res"},{"key":"1414_CR23","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1097\/JS9.0000000000001475","volume":"110","author":"K Ning","year":"2024","unstructured":"Ning K, Yu Y, Zheng X et al (2024) Risk factors of transient and permanent hypoparathyroidism after thyroidectomy: a systematic review and meta-analysis. Int J Surg 110:5047\u20135062. https:\/\/doi.org\/10.1097\/JS9.0000000000001475","journal-title":"Int J Surg"},{"key":"1414_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1055\/a-1245-7539","volume":"29","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Henneicke H, Fuss CT et al (2020) Novel treatment modalities in chronic hypoparathyroidism. Osteologie 29:283\u2013292. https:\/\/doi.org\/10.1055\/a-1245-7539","journal-title":"Osteologie"},{"key":"1414_CR25","unstructured":"European Medicines Agency (EMA) (2023) Yorvipath: EPAR\u2014product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yorvipath-epar-product-information_en.pdf"},{"key":"1414_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","volume":"16","author":"G Marcucci","year":"2016","unstructured":"Marcucci G, Della Pepa G, Brandi ML (2016) Natpara for the treatment of hypoparathyroidism. Expert Opin Biol Ther 16:1417\u20131424. https:\/\/doi.org\/10.1080\/14712598.2016.1238455","journal-title":"Expert Opin Biol Ther"},{"key":"1414_CR27","unstructured":"Deutsche Fachgesellschaft f\u00fcr Endokrinologie, Deutsche Gesellschaft f\u00fcr Nuklearmedizin, Deutsche Ges. f\u00fcr Kinderendkrinologie- und diabetologie (DGKED) e.V., et al (2012) S2k Leitlinie Operative Therapie benigner Schilddr\u00fcsenerkrankungen. https:\/\/register.awmf.org\/assets\/guidelines\/088-007l_S2k_operative_Therapie_benigner_Schilddruesenerkrankungen_2025-03-verlaengert.pdf"},{"key":"1414_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/0142159X.2017.1245856","volume":"39","author":"S Humphrey-Murto","year":"2017","unstructured":"Humphrey-Murto S, Varpio L, Gonsalves C, Wood TJ (2017) Using consensus group methods such as Delphi and nominal group in medical education research. Med Teach 39:14\u201319. https:\/\/doi.org\/10.1080\/0142159X.2017.1245856","journal-title":"Med Teach"},{"key":"1414_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12913-014-0534-0","volume":"14","author":"R Attieh","year":"2014","unstructured":"Attieh R, Gagnon M-P, Estabrooks CA et al (2014) Organizational readiness for knowledge translation in chronic care: a Delphi study. BMC Health Serv Res 14:534. https:\/\/doi.org\/10.1186\/s12913-014-0534-0","journal-title":"BMC Health Serv Res"},{"key":"1414_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3138\/cjpe.020.005","volume":"20","author":"CA Christie","year":"2005","unstructured":"Christie CA, Barela E (2005) The delphi technique as a method for increasing inclusion in the evaluation process. Can J Program Eval 20:105\u2013122. https:\/\/doi.org\/10.3138\/cjpe.020.005","journal-title":"Can J Program Eval"},{"key":"1414_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac102","author":"K Nagel","year":"2022","unstructured":"Nagel K, Hendricks A, Lenschow C et al (2022) Definition and diagnosis of postsurgical hypoparathyroidism after thyroid surgery: meta-analysis. BJS Open. https:\/\/doi.org\/10.1093\/bjsopen\/zrac102","journal-title":"BJS Open"},{"key":"1414_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11136-020-02607-1","volume":"30","author":"M Brod","year":"2021","unstructured":"Brod M, Waldman LT, Smith A, Karpf D (2021) Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Qual Life Res 30:277\u2013291. https:\/\/doi.org\/10.1007\/s11136-020-02607-1","journal-title":"Qual Life Res"},{"key":"1414_CR33","volume-title":"Fischbach\u2019s A Manual of Laboratory and Diagnostic Tests","author":"FT Fischbach","year":"2017","unstructured":"Fischbach FT, Fischbach MA (2017) Fischbach\u2019s A Manual of Laboratory and Diagnostic Tests, 10th edn. Lippincott Williams & Wilkins (LWW), Philadelphia","edition":"10"},{"key":"1414_CR34","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","volume":"105","author":"JP Bilezikian","year":"2020","unstructured":"Bilezikian JP (2020) Hypoparathyroidism. J Clin Endocrinol Metab 105:1722\u20131736. https:\/\/doi.org\/10.1210\/clinem\/dgaa113","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-024-03807-2","volume":"85","author":"M B\u00fcttner","year":"2024","unstructured":"B\u00fcttner M, Singer S, Taylor K (2024) Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review. Endocrine 85:80\u201390. https:\/\/doi.org\/10.1007\/s12020-024-03807-2","journal-title":"Endocrine"},{"key":"1414_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PROM.S179310","volume":"10","author":"T Coles","year":"2019","unstructured":"Coles T, Chen K, Nelson L et al (2019) Psychometric evaluation of the hypoparathyroidism symptom diary. Patient Relat Outcome Meas 10:25\u201336. https:\/\/doi.org\/10.2147\/PROM.S179310","journal-title":"Patient Relat Outcome Meas"},{"key":"1414_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40271-019-00388-5","volume":"13","author":"M Brod","year":"2020","unstructured":"Brod M, Waldman LT, Smith A, Karpf D (2020) Assessing the patient experience of hypoparathyroidism symptoms: development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom). Patient 13:151\u2013162. https:\/\/doi.org\/10.1007\/s40271-019-00388-5","journal-title":"Patient"},{"key":"1414_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s41687-025-00868-3","volume":"9","author":"C Trummer","year":"2025","unstructured":"Trummer C, Blaschke M, Quint D et al (2025) Normative values for the hypoparathyroidism patient questionnaire (HPQ28) in the German general population. J Patient Rep Outcomes 9:38. https:\/\/doi.org\/10.1186\/s41687-025-00868-3","journal-title":"J Patient Rep Outcomes"},{"key":"1414_CR39","doi-asserted-by":"publisher","first-page":"e10586","DOI":"10.1002\/jbm4.10586","volume":"6","author":"B Stamm","year":"2022","unstructured":"Stamm B, Blaschke M, Wilken L et al (2022) The influence of conventional treatment on symptoms and complaints in patients with chronic postsurgical hypoparathyroidism. JBMR Plus 6:e10586. https:\/\/doi.org\/10.1002\/jbm4.10586","journal-title":"JBMR Plus"},{"key":"1414_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-023-03443-2","volume":"82","author":"M B\u00fcttner","year":"2023","unstructured":"B\u00fcttner M, Krogh D, Siggelkow H, Singer S (2023) Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey. Endocrine 82:419\u2013426. https:\/\/doi.org\/10.1007\/s12020-023-03443-2","journal-title":"Endocrine"},{"key":"1414_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10245","volume":"4","author":"D Wilde","year":"2019","unstructured":"Wilde D, Wilken L, Stamm B et al (2019) The HPQ-development and first administration of a questionnaire for hypoparathyroid patients. JBMR Plus 4:e10245. https:\/\/doi.org\/10.1002\/jbm4.10245","journal-title":"JBMR Plus"},{"key":"1414_CR42","unstructured":"Rote Hand Brief Natpar (Parathyroidhormon) 100 Mikrogramm\/Dosis Pulver und L\u00f6sungsmittel f\u00fcr Injektionsl\u00f6sung: voraussichtlicher Lieferengpass ab 1. Juli 2022. https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2022\/rhb-natpar_oktober2022.html"},{"key":"1414_CR43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jbmr.4016","volume":"35","author":"DB Karpf","year":"2020","unstructured":"Karpf DB, Pihl S, Mourya S et al (2020) A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults. J Bone Miner Res 35:1430\u20131440. https:\/\/doi.org\/10.1002\/jbmr.4016","journal-title":"J Bone Miner Res"},{"key":"1414_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","volume":"38","author":"AA Khan","year":"2022","unstructured":"Khan AA, Rubin MR, Schwarz P et al (2022) Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 pathway trial. J Bone Miner Res 38:14\u201325. https:\/\/doi.org\/10.1002\/jbmr.4726","journal-title":"J Bone Miner Res"},{"key":"1414_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"Siggelkow H, Clarke BL, Germak J et al (2020) Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf) 92:159\u2013168. https:\/\/doi.org\/10.1111\/cen.14128","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01414-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01414-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01414-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:20:42Z","timestamp":1766755242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01414-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01414-5","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elena Tsourdi conducted clinical trials with Alexion, Amgen, Amolyt, Ascendis, Kyowa Kirin and UCB and has received honoraria for lectures or preparation of educational material from Alexion, Amgen, Ascendis Firma and UCB. Karin Amrein received speaker fees from Takeda in the past. Markus Ketteler provided research and clinical consultation for Shire (a Takeda company) and received speaker fees from Ascendis Firma. Tobias Vogelmann and Tino Schubert are owners and employees of LinkCare which received honoria by Ascendis Firma and Takeda. Heide Siggelkow\u00a0participated in advisory boards for\u00a0MSD, Lilly, Amgen, Servier, Takeda, UCB, Kyowa Kirin and received speaker fees by\u00a0MSD, Lilly, Amgen, GSK, Servier, Takeda, Alexion, Kyowa Kirin, UCB, Sandoz, Sanofi Aventis. Research support: Takeda. Christian Meier\u00a0participated in advisory boards for Alexion, Amgen, Ascendis Firma, Kyowa Kirin, UCB, and received speaker fees from Amgen, GedeonRichter and UCB. Michael C. Kreissl, and Annie Mathew state that they have no conflicts of interest with respect to the submitted manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No approval of research ethics committees was required to accomplish the goals of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"All participants in the Delphi process are co-authors of this publication. By contributing to the development and refinement of the consensus statements, each author has provided informed consent for the use and publication of their input.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}],"article-number":"107"}}